Merck's sacituzumab tirumotecan Reduces Death Risk by 32% in Endometrial Cancer Phase 3 Trial
Phase 3 clinical trial data for Merck's (MRK) antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), demonstrated a significant therapeutic benefit for patients with endometrial cancer. According to the TroFuse-005 trial results, the treatment reduced the risk of death by 32% when compared to standard chemotherapy in patients who had previously received prior therapies. The success of this trial highlights the potential of sacituzumab tirumotecan as a new standard of care for advanced endometrial cancer. This development is expected to strengthen Merck's oncology pipeline and could drive significant market interest in their antibody-drug conjugate (ADC) technology platform.
Tickers: $MRK
Topics: clinical trial results drug efficacy endometrial cancer oncology
Read the full article at Seeking Alpha
Part of the story Merck's sacituzumab tirumotecan Reduces Death Risk by 32% in Endometrial Cancer Phase 3 Trial (2 articles)